Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Jun 10, 2022 2:16pm
182 Views
Post# 34747814

RE:RE:Patients 20 & 21

RE:RE:Patients 20 & 21consultant99 wrote
My look based on the charts is 26 patients will be completed their 450 day scans by year end. 

Based on the goal of applying for BTD in Q4 once 25 scans have been completed Imam guessing the 25th will be done in November.


On a totally different topic I have recently been pondering on how patients can have a NR after a treatment. Surely the drug is absorbed by cancerous cells and activating it will kill them so what exactly happens to those where there is a NR? Why does it happen and are there tweaks to the process that might be found to make the treatment more effective?

Patients 21 to 24 were announced August 30/2021 so yes it is very possible that patients 25 & 26 were given their first treatment before the end of September which gives them 1 year by September 30/2022 plus 90 days = 450 days by December 31/2022
<< Previous
Bullboard Posts
Next >>